Please enable Javascript to use all features and improve your user experience.
ADO 2024
Programme
People
Search
EN
All people
Mark Salvati
Tarrytown, NY, US
Regeneron Pharmaceuticals, Inc.
Sort by Type
Date
Further involvements
25/09/2024
ePoster
eP143
A Phase 3 trial of fixed dose combination of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma
25/09/2024
ePoster
eP167
A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy